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The 5-HT1E receptor gene was cloned in 1992 but little information on the receptor exists 
as no specific pharmacological tool for the receptor has been described. In this study, a 
model of the G-protein coupled 5-HT1E receptor has been created by homology modeling 
using the crystallised structure of bovine rhodopsin as a template structure and a docking 
simulation placing 15 ligands in the putative binding site of the model has been 
performed in order to study structure activity relationships. 
 
The model of the 5-HT1E receptor shows that the receptor consists seven transmembrane 
helices forming a conserved helical bundle and one additional cytoplasmic helix in the 
receptor C-terminus. The putative binding site of the receptor is buried in between the 
transmembrane helices and residues of transmembrane helices three, four, five, six and 
seven are especially important for ligand binding to the receptor. The protonated amine 
terminal moieties of the biogenic amines are assumed to interact with the carboxyl 
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ECL Extracellular loop 
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In order for the cells of the body to cooperate properly, cell signalling must occur. Cells 
signal to each other through compounds in the extracellular space, which the cells detect and 
respond selectively to. Examples of endogenous signals may be hormones, growth factors 
and cytokines, and the responses of a cell to external signals may be changes in gene 
expression, enzyme activity or in ion channel activity. When the ligands are large or 
hydrophilic such that they cannot penetrate the lipid plasma membrane, proteins in the 
plasma membrane may act as signal transducers by coupling the external signal to the 
biochemical responses of the cell. Hydrophobic ligands, such as some hormones, or gases 
penetrate the lipid bilayer directly and act on intracellular receptors. 
 
The cloning of genes expressing receptors and ion channels, together with pharmacological 
studies, has shown that the diversity among the target proteins is great. This molecular 
diversity of the target proteins raises the possibility of discovering drugs that act selectively 
on the different structures. Selectivity is very important from a pharmacological viewpoint, as 
it means that one target structure can be targeted without affecting other structures, thereby 
(1) being used as a tool in determining the function and distribution of the different isoforms 
of the proteins and (2) later on, reducing the side effects of a drug by making the drug 
selective for only one isoform.  
 
1.1 G-protein coupled receptors 
 
There are four main types of target proteins that endogenous and exogenous compounds can 
act on, namely ion channels, receptors, enzymes and transport proteins. Receptors are ‘the 
sensing elements in the system of chemical communication that coordinates the function of 
all the different cells in the body’ (Rang 2003). Of the receptor types, ligand-gated ion 
channels (ionotropic receptors) and G-protein coupled receptors (GPCRs; metabotropic 
receptors) are the main receptor drug targets. Kinase-linked receptors and nuclear receptors 





Figure 1. Schematic representation of a family A receptor in the cell membrane based on the packing 
arrangement of TMHs observed in the 2.6 Å crystal structure of rhodopsin (Pdb code 1L9H). The 
transmembrane helices are displayed as cylinders; ECL: extracellular loop; ICL: intracellular loop; 8: 
cytoplasmic C-terminal α helix. The putative binding site region is located between the helices. 
(Kristiansen 2004) 
 
The superfamily of G-protein coupled receptor consists of proteins that share a common 
membrane topology, namely a nonparallel heptahelical transmembrane topology connected 
by extracellular and intracellular loops. The N-terminus is located extracellularly, and the C-
terminus is intracellular. The helices are tilted in the membrane to obtain a proper helical 
packing and function of the receptor, and are arranged in an anticlockwise arrangement when 
viewed from the extracellular side (Kristiansen 2004). Figure 1 show a schematic 
representation of the helical bundle of rhodopsin in the plasma membrane. 
 
For comparison of the family A G-protein coupled receptor sequences, a numbering system 
in which the positions of the residues relative to a reference residue within each 
transmembrane helix, is used. The reference residues of transmembrane helices 1, 3, 4, 6 and 
7 are the most conserved residues in each helix, whereas the reference residues of 
transmembrane helices 2 and 5 are the second most conserved amino acids in these helices 
(Kroeze et al. 2002).  
 
In order to determine if a sequence of unknown structure is a G-protein coupled receptor, a 
hydropathy plot of the receptor sequence can be generated to identify the possible segments 
of the sequence that may correspond to the seven helices, the hallmark of G-protein coupled 
receptors. A hydropathy plot is generated by calculating hydropathy indices for each amino 
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acid in the sequence and then plotting these indices against the residue numbers. The 
hydropathy index is the mean value of the hydropathy of the amino acids within a window 
around each position, i.e. if the window size is 9, the hydropathy index of amino acid number 
five in this window is calculated. Hydrophobic amino acids have high positive hydropathy 
scores, whereas hydrophilic amino acids have negative hydropathy scores and in 
transmembrane helices the hydropathy index is high for a number of consecutive positions in 
the sequence. The most commonly used hydropathy scale for calculation of the hydropathy 
indices is the scale created by Kyte-Doolittle, in which the score of each amino acid has been 
determined by the use of experimental data (Branden 1999). 
 
Table 1 shows the hydropathy scores of the amino acids used to generate hydropathy plots 
using the Kyte-Doolittle method and figure 6 shows the hydropathy plot of the 5-HT1E 
receptor sequence. 
 
Table 1. Amino acid hydropathy scores based on the values reported by Kyte-Doolittle (Branden 1999). 
 
Residue Hydropathy score 
Isoleucine (I) 4.5 
Valine (V) 4.2 
Leucine (L) 3.8 
Phenylalanine (F) 2.8 
Cysteine (C) 2.5 
Methionine (M) 1.9 
Alanine (A) 1.8 
Glycine (G) -0.4 
Threonine (T) -0.7 
Tryptophan (W) -0.9 
Serine (S) -0.8 
Tyrosine (Y) -1.3 
Proline (P) -1.6 
Histidine (H) -3.2 
Glutamic acid (E) -3.5 
Glutamine (Q) -3.5 
Aspartic acid (D) -3.5 
Asparagine (N) -3.5 
Lysine (K) -3.9 





1.1.1 Signal transduction by GPCRs 
 
A suggested receptor activation mechanism involves a highly conserved motif at the 
intracellular end of transmembrane helix 3 (TMH3), the DRY motif, which consists of 
residues D3.49, R3.50 and Y3.51. This motif is present in all 5-HT receptors as well as in 
rhodopsin, although the residue in position 3.49 in rhodopsin is a glutamic acid, not an 
aspartate. Studies of the rat 5-HT2A receptor suggest that the arginine in this motif is 
involved in a strong ionic interaction with a glutamic acid residue at the intracellular end 
of transmembrane helix 6, E6.30, which is thought to stabilise the inactive state of the 
receptor. The disruption of this interaction produces a highly constitutive active receptor 
with increased potency for agonists. The interaction between R3.50 and E6.30 brings the 
cytoplasmic ends of transmembrane helix 3 and 6 close together, primarily through the 
movement of the sixth transmembrane helix via a hinge at residue P6.50, the proline 
kink. D3.49A, E6.30Q, E6-30L, and E6.30N mutations disrupt the interaction and 
increase the constitutive activity of the receptor, probably by allowing the TMH3 and 
TMH6 to move apart (Kroeze et al. 2002). Figure 9 shows the localisation of  R3.50 and 
E6.30 in the 5-HT1E receptor. 
 
The third intracellular loops of GPCRs (Kristiansen 2004) have been found to be important 
for coupling to heterotrimeric GTP-binding proteins, G-proteins in short, that mediate the 
intracellular actions of the receptors. Heterotrimeric G-proteins are composed of α, β, and γ 
subunits; the β and γ subunits being closely associated and may be regarded as one functional 
unit. There are at least twenty-eight distinct G-protein α subunits, five different β subunits 
and twelve different γ subunits which combine into a variety of functional G-proteins 
(Cabrera-Vera et al. 2003). The G-proteins may be inhibitory or stimulatory in their actions, 
and both α-GTP and the βγ complexes may target different structures in the cells, including 
ion channels and enzymes. Figure 3 shows some of the effects G-protein activation leads to 
in cells. 
  
The activation/inactivation cycle is similar for all G-proteins. An inactive complex consisting 
of the three G-protein subunits is present when GDP is bound to the α subunit and this 
complex is associated with the receptor protein. Binding of an agonist to the receptor causes a 
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conformational change in the receptor and increases the affinity of the receptor for the G-
protein. This leads to the rapid release of GDP from the α subunit and replacement by GTP, 
causing a reduction in affinity of the α subunit for the βγ complex, leading to dissociation of 
the G-protein heterotrimer into two subunits, namely the GTP-α subunit and the βγ subunit. 
These subunits can act on several effector proteins, including adenylyl cyclase, 
phospholipase C, tyrosine kinases, and ion channels, and activate or inactivate the proteins. 
The effects may be initiated directly by the G-protein subunits, or be further downstream in 
the signalling cascade by the actions of specific second messengers (Kristiansen 2004). 
 
The activation cycle ends when the intrinsic GTPase of the α subunit hydrolyses GTP to 
GDP, causing the dissociated subunits to reassemble into an inactive complex, thereby 
ending the signal. This process may be accelerated by RGS (Regulators of G-protein 
signalling) proteins (Cabrera-Vera et al. 2003). 
 
Figure 2 shows the G-protein activation/inactivation cycle. 
 
 
Figure 2. Receptor-mediated G protein activation. The interaction of ligand (A) with its cell surface 
receptor (R) facilitates the coupling of the activated receptor (R*) with intracellular heterotrimeric G 
proteins, which in turn promotes the exchange of GDP for GTP on the G α subunit and the dissociation of  
the Gα-GDP from Gβγ and the receptor. Termination of the signal occurs when the γ-phosphate of GTP is 
removed by the intrinsic GTPase activity of the Gα subunit, leaving GDP in the nucleotide binding pocket 
on Gα. Gα then reassociates with Gβγ and the cycle is complete. RGS (Regulator of G-protein Signalling) 
proteins accelerate the intrinsic GTPase activity of Gα subunits, thereby reducing the duration of signalling 




Figure 3. Prototypical signalling enzyme linkages of the G-protein coupled 5-HT receptors. AC: adenylyl 
cyclase; PKA: protein kinase A; PLA: phospholipase A; PLCβ: phospholipase Cβ; AA: arachidonic acid; 
PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol triphosphate; DAG: diacylglycerol; PKC: protein 
kinase C (Raymond et al. 2001) 
 
Adenylyl cyclase is a transmembrane enzyme that catalyses the conversion of ATP to the 
second messenger 3’,5’-cyclic AMP (cAMP), triggering the intracellular signalling pathways 
leading to the intracellular responses of the cells to the external stimulus. Figure 3 shows that 
activation of the 5-HT1 and 5-HT4, 5-HT6, and 5-HT7 receptors may stimulate or inhibit the 
adenylyl cyclase through G-proteins.  
 
1.1.2 Family A of GPCRs  
 
The superfamily of GPCRs consists of seven families of mammalian GPCRs, namely family 
A, B and C, large N-terminal family B-7TM (LNB-7TM), the frizzled/smoothened [F/S] 
family, vomeronasal 1 receptor [V1R] family, and the taste 2 receptor [T2R] family 
(Kristiansen 2004). Rhodopsin and the 5-HT receptors belong to the largest family, family A, 
which is also called the rhodopsin family. Included in this family are receptors for ligands 
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such as photons, odorants, biogenic amines, different hormones such as LH, FSH, and TSH, 
peptides, which is the largest subgroup and include neurotransmitters, hormones, and 
paracrines, and ligands for protease-activating receptors (Kristiansen 2004). The binding sites 
for most small molecule ligands of the family A GPCRs are buried in between the 
transmembrane helices, closer to the extracellular side than the cytoplasmic side of the 
membrane (Kristiansen 2004).  
 
1.2 The 5-HT system 
 
5-HT is the neurotransmitter for which the number of receptors is highest (Bockaert et al. 
2006). The importance of 5-HT is reflected in the number of species using 5-HT as a 
signalling molecule –coelenterates, arthropods, molluscs, tunicates, and vertebrates all use 5-
HT for signalling– and the number of 5-HT receptors found within each species. 15 human 5-




5-HT (5-hydroxytryptamine, serotonin) is a monoamine that is acts as a neurotransmitter in 
the CNS and as a paracrine in peripheral vascular systems. Even though 5-HT is present in 
the diet, most of it is metabolised before entering the bloodstream. In the body, 5-HT is 
synthesised from tryptophan via 5-hydroxytryptophan by the enzymes tryptophan 
hydroxylase and a non-specific amino acid decarboxylase, respectively. Excretion of 5-HT in 
urine occurs after 5-HT is metabolised by monoamine oxidase to 5-hydroxyindole 
acetaldehyde and then by aldehyde dehydrogenase to five-hydroxyindoleacetic acid (5-
HIAA) (Rang 2003).  
 
In the CNS, the cell bodies of the neurons that release 5-HT are grouped into the pons and 






1.2.2 5-HT receptors  
 
Currently, 12 human 5-HT receptors have been cloned and classified into seven 5-HT 
receptor families. Six families encode G-protein coupled 5-HT receptors, while one family, 
the 5-HT3 family, are ionotropic channels and are not discussed here.  
 
The 5-HT1 receptor family is the largest 5-HT receptor family and contains five human 5-HT 
receptors, termed 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F. The former 5-HT1C family has 
been reclassified as the 5-HT2C receptor based on sequence similarities to the 5-HT2A and 5-
HT2B receptors and similar second messenger systems (Raymond et al. 2001). In addition to 
the 5-HT1 receptors, three human 5-HT2 receptors, the 5-HT2A,, 5-HT2b, and 5-HT2C receptors, 
and one human 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptor, have been cloned.  
 
Most of the G-protein coupled 5-HT receptors are expressed not only in humans or 
mammalians but also in many other species, such as rat and guinea pig. The 5-HT1D receptor, 
for instance, is found in mouse, rabbit, and rat in addition to human species, whereas the 5-
HT1E receptor has so far only been cloned in the human and guinea pig genomes (Bai et al. 
2004). The human and guinea pig 5-HT1E receptors share 95 percent sequence homology. 
 
In addition to the 12 human G-protein coupled 5-HT receptors that have been cloned, some 
5-HT receptors are also modified post-genomic by alternative splicing and mRNA editing, 
which results in even more diversity. The 5-HT2C receptor is the only known GPCR that is 
regulated by mRNA editing, whereas splice variants of both the 5-HT4 receptor and the 5-
HT7 receptors have been described (Bockaert et al. 2006). The tissue specific mRNA editing 
involves nucleotide substitution, most frequently adenosine to inosine, or cytidine to uridine, 
and appears to regulate the pattern of intracellular signalling. Of today, ten functional splice 
variants of the 5-HT4 receptor have been described. The different forms of the 5-HT4 receptor 
vary in their C-termini, and the different variants may be in charge of the fine-tuning of 
signal transduction as they interact with specific intracellular proteins. The 5-HT7 receptor is 
also modified by alternative splicing, also resulting in three receptors differing in their C-
termini. The 5-HT1 genes are intronless and cannot be modified by alternative splicing 
(Bockaert et al. 2006). 
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The genes encoding the 5-HT1 receptors constitute a subgroup of genes that were 
diverged from a common ancestor (Bockaert et al. 2006). The 5-HT receptors vary in 
length from 358 to 482 amino acids, but still 33 residues are invariant and additional 27 
residues that are at least 80 percent conserved among these receptors (Kroeze et al. 2002). 
Figure 4 shows a phylogenetic tree showing the evolutionary relationship of the human 5-
HT receptors and bovine rhodopsin.  
 
 
Figure 4. Evolutionary tree generated by ICM by sequence alignment of the human 5-HT receptors and 
heterodimeric bovine rhodopsin amino acid sequences. 1u19 a,b: rhodopsin; sp_: ExPASy accession code 





The 5-HT1E receptor shares 39 percent sequence homology with the 5-HT1A receptor, 47 
percent (64 percent in transmembrane regions) with the 5-HT1B and 5-HT1D receptors, and 70 







Table 2. Reference residues and residues with possible ligand binding functions and receptor activation 






Assumed function Selected references 
1.50 N40 Reference residue  
2.50 D68 Reference residue 
Receptor activation?  
(Mirzadegan et al. 2003) 
(Kroeze et al. 2002) 
3.25 C93 Disulfide bridge 
(with C173 in ECL2) 
(Kroeze et al. 2002) 
(Mirzadegan et al. 2003) 
3.28 W98 Hydrophobic ligand 
binding pocket 
(Kristiansen 2004) 
3.32 D102 Important for ligand 
binding. Stabilisation 
of protonated amine 
moiety of ligands. 
(Kristiansen 2004) 








Receptor activation  
Reference residue 
(Kroeze et al. 2002) 
 



























Table 2 continued. Reference residues and residues with possible ligand binding functions and receptor 






Assumed function References 































(Kroeze et al. 2002) 
7.36 D327 Ligand binding (Kristiansen 2004) 
(Kroeze et al. 2002) 





















(Mirzadegan et al. 2003) 
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Table 1 shows residues that have been suggested to be involved in ligand binding or 
receptor activation. Especially important residues include residues D102 (3.32) and Y334 
(7.43), which are fingerprint residues of biogenic and trace amine receptors. These 
residues have been suggested to play important roles in ligand binding. The side chains of 
these residues may function to stabilise the amine terminal moieties of the biogenic 
ligands that bind to these receptors and they may also act as a receptor activation switch 
(Kristiansen 2004). Many aromatic residues have also been proposed to form a 
hydrophobic ligand binding pocket around the ligands. Studies also suggest that residues 
R3.50 and E6.30 and residues D2.50 and N7.49 may interact through ionic interactions 
and hydrogen bonding, respectively, and may play roles in receptor activation (Kroeze et 
al. 2002). Another study suggests that two residues in the sixth transmembrane helix may 
account for some pharmacological differences between the 5-HT1E and the 5-HT1B 
receptors, namely the residues K310 (6.54) and E311 (6.55) in the 5-HT1E receptor 
sequence (Kroeze et al. 2002). 
 
The N- and C-termini of the 5-HT receptors are, together with the extracellular and 
intracellular loops, the least conserved regions of GPCRs. The amino acid residues in the 
extracellular loops vary among the receptors, as they may be important for specific ligand 
recognition. The intracellular loops show somewhat more similarity, suggesting a 
common coupling mechanism to G-proteins (Mirzadegan et al. 2003). The third 
intracellular loop is the most probable site of G-protein coupling in 5-HT receptors 
(Kroeze et al. 2002). 
 
Of the 5-HT1 receptors, the 5-HT1A receptor has been best characterised. The reason for 
this is that there are many specific pharmacological tools for the receptor; in addition, the 
receptor was the first of the 5-HT receptors to be cloned. Many studies, including various 
physiological, clinical, behavioural, and pharmacological studies, show that the 5-HT1A 
receptor plays potential roles in conditions such as depression and anxiety and also have 
potential roles in neuroendocrine function and thermoregulation, vasoreactive headaches, 
sexual behaviour, food intake, and immune function (Raymond et al. 2001). The 5-HT1A 
receptors are found in the highest densities in the limbic system, where the receptors are 
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located both pre-synaptically (5-HT1A auto-receptors on the soma and dendrites of 5-HT 
neurons) and post-synaptically. 5-HT1A auto-receptors control the synthesis and release of 
5-HT, and selective serotonin reuptake inhibitors (SSRIs), which currently are the most 
commonly used drugs for the treatment of depression (Rang 2003), are in fact efficient 
only after desensitisation of the 5-HT1A auto-receptors.  
 
5-HT1A receptor activation stimulates neurogenesis, the creation of new neurons, in the 
hippocampus (Bockaert et al. 2006). Post mortem and brain imaging studies reveal that 
depressed or anxious patients have loss of neurons in the prefrontal cortex and 
hippocampus. An observation that stress, which may cause depressive episodes in 
humans, also decreases the hippocampal neurogenesis, suggest that this process may be 
involved in the pathogenesis of mood disorders (Santarelli et al. 2003). Neurogenesis has 
been shown to increase in response to antidepressants and 5-HT1A receptor agonists are 
used for the treatment of anxiety. The azaspirodecanedione class of 5-HT1A receptor 
acting drugs, which includes buspirone, is used for the treatment of anxiety. Buspirone is 
a partial agonist at the post-synaptic 5-HT1A receptors and a full agonist at the 5-HT1A 
autoreceptors {Felleskatalogen.no,  #47}. These selective 5-HT1A receptor agonists have 
fewer side effects than some of the other common antianxiolytic drugs, such as the 
benzodiazepines. 
 
1.2.3 The 5-HT1E receptor 
 
The intronless human 5-HT1E receptor gene was cloned in 1992 (Levy et al. 1992) 
(McAllister et al. 1992) (Zgombick et al. 1992). The human 5-HT1E receptor is a 365 amino 
acid long G-protein coupled receptor that shares greatest sequence homology with the 
receptors of the 5-HT1 receptor family. As seen in figure 4, the 5-HT1E receptor protein shows 
the highest sequence homology with the 5-HT1F receptor and lowest sequence homology with 
the 5-HT1A receptor among the 5-HT1 receptor family members.  
 
Little is known about the function or distribution of the 5-HT1E receptor protein as no 
selective ligands for the receptor yet have been described. The 5-HT1E receptor has been 
shown to inhibit adenylyl cyclase at low concentrations in transfected HeLa and BS-C-1 
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cells. It has also been shown that high concentrations of agonist can stimulate the adenylyl 
cyclase in BS-C-1 cells (Raymond et al. 2001).  
 
1.3 Structure determination 
 
1.3.1 Structure determination of membrane proteins 
 
The RCSB PDB database (Berman et al. 2000) contains the structure of every protein 
experimentally determined, either by x-ray crystallography, nuclear magnetic resonance 
(NMR) spectroscopy or electron microscopy. The database also contains experimentally 
determined structures of nucleic acids (1676 structures) and of protein/nucleic acids 
complexes (1585 structures). 34 other structures, e.g. the structure of the glycoprotein 
antibiotic vancomycin, the connective tissue agarose double helix, and the carbohydrate 
cycloamylose, are also included in the database. Of October 3rd 2006, there are 35,909 
protein structures deposited in the PDB database and nearly ninety percent of these have been 
determined by x-ray crystallography methods. However, of these nearly 36,000 deposited 
structures, under 500 are membrane proteins. As most current drug targets are membrane 
proteins, much work is being done in determining the structure of the membrane proteins to 
better understand how drugs and endogenous compounds act and designing drugs that act 
more selectively, thereby reducing unwanted side effects of drugs. 
 
The three-dimensional structures of membrane proteins are usually difficult to determine 
using experimental methods such as x-ray crystallography. One of the reasons is that 
crystallisation involves solving the proteins in an aqueous solution and then removing the 
solution slowly in order to generate crystals. Membrane proteins come from a lipid 
environment and their surfaces have both hydrophobic and hydrophilic properties, making 
the proteins insoluble in the aqueous buffer and denature in organic solvents. In order to 
crystallise membrane proteins, detergents and small amphipathic molecules are added to the 
aqueous solution. The hydrophobic parts of the detergents bind to the hydrophobic parts of 
the proteins whereas the hydrophilic parts of the detergents face the surrounding solution and 
give the protein-detergent complex an essential hydrophilic surface while burying the 
hydrophobic parts. Addition of small amphipathic molecules to protein-detergent solutions 
may promote crystallisation of some proteins, probably by facilitation proper packing 
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interactions between the molecules in all three dimensions in a crystal (Branden 1999). 
Addition of detergent is necessary for maintaining the structural integrity of the membrane 
protein outside the lipid bilayer but it is also adds flexibility to the complex and this normally 
means that obtaining a crystal that diffracts with a high resolution is hard. 
 
Obtaining membrane proteins in sufficient quantities for crystallisation may also be 
difficult. Membrane proteins are usually not expressed in great amounts in cells and must 
be over-expressed in expressing systems in order to obtain sufficient amounts of the 
protein for crystallisation. For some proteins, receptors especially, over-expression of the 
proteins may strongly stimulate the cells, causing the cells to undergo apoptosis. 
Receptors may also be difficult to over-express. In contrast to X-ray crystallography, 
NMR is primarily limited to relatively small proteins, usually smaller than 25 kDa, 
making it unsuitable for predicting the structure of most proteins. 
 
One G-protein coupled receptor has been crystallised and the structure solved by x-ray 
diffraction with high resolution, namely the inactive form (the cis form) of the family A 
bovine membrane protein rhodopsin, the visual pigment in rod photo-receptor cells. 
Rhodopsin was crystallised using the hanging-drop vapour diffusion method to a resolution 
of 2.2 Å (PDB id 1U19) with the detergent heptylthioglucoside (Okada et al. 2004). 
Sequence comparison and molecular modeling studies support the hypothesis that most 
family A members are folded in the same manner as rhodopsin (Kristiansen 2004). The 
structure of rhodopsin is the only crystal structure of any GPCR that include the seven 
transmembrane segments, and bovine rhodopsin is used as a template structure in the 
modeling of GPCRs. 
 
1.3.2 Molecular modeling  
 
Molecular modeling is ‘the generation, manipulation and representation of three-dimensional 
molecular structures and their associated physical, chemical, biological and pharmacological 
properties’ (Ravna 2006). The homology modeling approach is based on the observation that 
structure is more conserved than sequence, such that a known protein structure can be used to 
construct a model of a homologous protein. The known protein structure is termed the 
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‘template’ structure, whereas the protein with unknown structure is the ‘target’ protein. 
Homology modeling of a membrane protein is done by aligning the target protein with the 
amino acid sequence of a homologue membrane structure with known folding pattern, having 
the start and endpoints of transmembrane domains predicted, and building a model based on 
this alignment.  
 
Molecular mechanical calculations, which are calculations on atomic nuclei, and quantum 
mechanical calculations, which are calculations on the electronic systems of molecules, 
are both included as techniques in molecular modeling. The Laws of thermodynamics 
state that molecules spontaneously seek the lowest energy and by performing energy 
minimisation calculations on the model, the lowest energy conformation of the model is 
calculated. Molecular dynamics is the simulation of molecular motion during a short 
period of time and is used to refine the model further (Ravna 2006).   
 
1.3.3 Structure prediction using ICM and AMBER 
 
Programs such as ICM and AMBER that are used to generate three-dimensional models and 
refine them, uses force fields that are determined through experimental work and high-level 
quantum mechanical calculations. Force fields are the functional form and parameter sets that 
are used to describe the potential energy of a system of atoms. The basic functional form of 
force fields includes bonded terms, which relate to atoms that are linked by covalent links, 
whereas the nonbonded terms describe the long-range electrostatic van der Waals forces. The 
specific composition of the terms depend on the force field, but a general form for the total 
energy can be written as: 
 
Etot = Ecovalent + Enoncovalent  
 




Force fields also define parameter sets for each atom in a model. The parameter sets include 
variables for atomic mass and partial charge for each atom, and equilibrium bond lengths and 
angles for pairs, triplets, and quadruplets of bonded atoms. For instance, force fields include 
distinct bonding patterns for an oxygen atom in a carbonyl group and in a hydroxyl group. 
The parameter sets are derived from studies on small organic molecules, which are more 
manageable for experimental studies and quantum mechanical calculations. 
 
The ICM software package can be used to predict the structure of a protein by homology 
modeling when there is no detailed three-dimensional structure of the target available, which 
is the case for most membrane proteins. Included in the ICM package is an all atom internal 
force field, which is a force field that provides parameters for all atoms in the system, 
hydrogen included. In addition, ICM contains the MMFF94 force field. After model building, 
ICM may be used in energy refinement of the generated models and for docking of small 
flexible ligands, see later paragraph.  
 
The AMBER package consists of a set of molecular mechanical force fields and a 
package of molecular simulation programs. AMBER may be used to perform energy 
minimisations and molecular dynamics studies and for analysing the results. There are 
three main steps in AMBER simulations, namely preparation, simulation and analysis, 
and different programs of the AMBER package carry out the different steps. During the 
preparation for molecular dynamics each atom in the molecule is assigned an atom or 
particle type. A coordinate file (prmcrd), which contains the Cartesian coordinates of all 
the atoms, and a parameter-topology file (prmtop), which contains all other information 
(atom names and masses, force field parameters, lists of bonds, angles, and dihedrals are 
needed, as well as additional bookkeeping information) needed to compute energies and 
forces are generated during the preparation phase. The main preparation programs in 
AMBER are ANTECHAMBER and LEaP, which functions include assembling force 
fields for residues or molecules that are not defined otherwise and construction of 
biological molecules. ANTECHAMBER programs include antechamber, which performs 
molecular conversion (for example, conversion of a pdb file to a prep file or a Gaussian 
input file) and assigns atom type and generates charge. The parmchk program is used to 
assign an addition force field (in a frcmod file) if parameters are missing in the prep file. 
 25
 
AMBER force fields have limited parameters for organic molecules and have for that reason 
not been widely used in drug design and other studies of ligand-protein or ligand-DNA 
interactions. Another force field that covers most drugs, the GAFF (General AMBER force 
field) force field, is used when constructing the ligands for binding energy calculations and 
molecular docking studies (Wang et al. 2004).  
 
The Gaussian 03 program uses the HF/6-31G* basis set for performing quantum 
mechanical calculation on the ligands for assignment of RESP charges in antechamber. 
RESP charges are preferred for AMBER simulations. The AM1-BCC charge method 
imitates the HF/6-312G* basis set for calculations of electrostatic potential of a molecule 
and quickly generates atomic point charges that may be used for computer simulations 
(Jakalian et al. 2002). The ligand charges are calculated using the AM1-BCC method for 
molecular docking in ICM.  
 
1.3.4 Molecular docking 
 
Molecular docking aims to predict the structure of the intermolecular complex that is formed 
between two or more molecules and has become a useful tool in structure-based drug design 
and discovery (Sousa et al. 2006). When performing molecular docking, protein flexibility is 
a critical aspect. Proteins are not rigid structures and ideally the proteins should be flexible 
during the docking simulations. However, introducing flexibility in the macromolecular 
proteins during docking is not yet possible in ICM, as the computational workload will be 
great. Instead docking studies in ICM are performed using a flexible ligand and a rigid 
receptor protein. 
 
1.3.5 Ramachandran plot 
 
Ramachandran plots, where the psi and phi angles of amino acid residues are plotted 
against each other, may be constructed to evaluate a model built by homology modeling. 
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Amino acids are linked together by covalent bonds at the Cα atoms and the only degrees 
of freedom they have are rotations around these bonds, i.e. around the Cα-C’ bond (psi, 
ψ) and the N-Cα bond (phi, φ), as the CO-NH (the peptide bond) is rigid and planar due 
to double bond character. In a Ramachandran plot, the angle pairs ψ and φ are plotted 
against each other in a diagram called a Ramachandran plot, which shows allowed 
combinations of the ψ and φ angles. Most combinations of ψ and φ angles for an amino 
acid are not allowed because they cause steric collisions between the side chains and 
main chain. Each point in the Ramachadran plot represents psi and phi values for an 
amino acid residue (Branden 1999). 
 
α helices in proteins are found when a stretch of consecutive residues all have the φ,ψ  
angle pair approximately -60° and -50°, corresponding to the allowed region in the 
bottom left quadrant of the Ramachandran plot. In the Ramachandran plot, left-handed α 
helices are seen in the upper right quadrant of Ramachandran plots, whereas β strands are 
seen in the upper left quadrant of the plot. 
 
Residues that may be expected to be located outside the allowed regions of the 
Ramachandran plot are glycine and proline. The glycine side chain consists of only a 
hydrogen atom and steric collisions do not occur that often as with the other amino acid 
residues that have longer side chains. In the case of proline, the side chain is bonded to 
the main chain nitrogen atom and forms a ring structure, thereby preventing the nitrogen 
atom from participating in hydrogen-bonding and also providing some sterical hindrance 











2. AIM OF STUDY 
 
Insight into ligand-receptor interactions is of pivotal importance for designing new ligands 
with therapeutic potential. In order to study these interactions three-dimensional structural 
information about the receptor structure is necessary. The detailed three-dimensional 
structure of the 5-HT1E receptor is not known, but the x-ray crystallographic structure of 
bovine rhodopsin, which shares the same three-dimensional topology as the 5-HT1E receptor, 
gives the possibility of using the homology modeling approach to construct a three-
dimensional model of the 5-HT1E receptor. 
 
The specific aims of the present study were: 
 
1. Construction of a model of the 5-HT1E receptor using molecular modeling 
2. Docking of a series of ligands into the putative binding site of the 5-HT1E receptor 
model using automatic docking 




















3.1 Construction of the 5-HT1E receptor model in ICM 
 
The Molsoft ICM program package version 3.4-4 was used to align the rhodopsin and 5-
HT receptor sequences and to build the model of the 5-HT1E receptor based on this 
sequence alignment. The reason for aligning all 5-HT receptor amino acid sequences and 
bovine rhodopsin was to avoid mismatching of the 5-HT1E receptor amino acid sequence 
and rhodopsin, which is more likely to occur when only the two amino acid sequences are 
aligned. The crystallised structure of bovine rhodopsin B chain (PDB id: 1U19) was used 
as the template structure for homology modeling of the 5-HT1E receptor target. The 
rhodopsin protein is a heterodimeric protein but as the chains do not differ much, the A 
chain just as well could have been used for the modeling of the 5-HT1E receptor. The 
amino acid sequences of the other 5-HT receptors and of rhodopsin chain A were 
removed from the alignment before building of the model.  
 
The 5HT1E receptor and rhodopsin structures were aligned with ICM and the alignment 
was manually adjusted to avoid gaps in the helices and making sure that the highly 
conserved residues in each transmembrane helix were aligned together. The alignment 
was also adjusted so that the two cysteine residues that form the disulfide bridge, C95 and 
C173 in the 5-HT1E receptor sequence, were aligned with the corresponding cysteine 
residues in the rhodopsin sequence. The model of 5-HT1E receptor was constructed using 
the Build model function in ICM. In ICM, the most conserved domains are used as ‘rigid 
bodies’ by using the average position of Cα atoms in the domain to keep the most 
conserved regions fixed during the building procedure. The loops were constructed by 
homology modeling with existing loops in the PDB database. The loop sequences were 
used as input for searching the PDB database for corresponding sequences, and the loops 
were selected based in internal energy and its interaction energy with loop environments 
on the model. Prediction of the loops in ICM is very unreliable when the loops have more 
than three residues.  
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3.2 Refinement of the 5HT1E receptor model by ICM and AMBER 
 
The refineModel macro in ICM was used to energy refine the 5-HT1E receptor model 
generated in the previous step. By using this macro, the side chains are globally optimised 
and the backbone annealed in order to find the lowest energy conformation of the model. The 
first step of refinement is sampling of the side chain conformational positions using 
‘Montecarlofast’. In the second step, the backbone molecules are randomly moved repeated 
times (harmonic restraints pull the atoms to static points in space represented by the 
corresponding atoms in the template), followed by a local energy minimisation. The complete 
energy for the structure is then calculated. The resulting structure is either accepted or 
discarded based on its energy and temperature (a high temperature indicates unfavourable 
structures). After the annealing of the backbone, a second side chain sampling is performed. 
 
Following the refinement of the 5-HT1E receptor model in ICM, the model was further 
refined by using the AMBER8 package to perform molecular dynamics on the model. Before 
running molecular dynamics on a structure generated by homology modeling in ICM, an 
energy minimisation in AMBER needed to be performed. To minimise the structure, the 
SANDER program of AMBER was used. The first minimisation was a short steepest descent 
minimisation that was performed not to reach energy minimum but to relieve possible bad 
steric interactions in the structure. The NCYC flag controls which minimisation algorithm 
SANDER uses. When NCYC is lower than MAXCYC, which is the total number of 
minimisation cycles, SANDER uses the steepest descent algorithm for the first NCYC steps, 
then switches to conjugate gradient algorithm for the remaining. The 5-HT1E receptor model 
was minimised 250 cycles using the steepest descent algorithm, followed by 250 steps of 
conjugate gradient minimisation during the first energy minimisation in AMBER (MAXCYC 
500; NCYC 250). The second energy minimisation of the 5-HT1E receptor was a longer 
conjugate gradient minimisation, where the first 500 minimisation cycles were performed 
using the steepest descent algorithm, followed by 2000 cycles of conjugate gradient 
minimisation (MAXCYC 2500; NCYC 500).  
 
After energy minimisations, the SANDER program of AMBER was used to perform a 
implicit solvent Generalised Born molecular dynamics simulation. During the molecular 
dynamics simulation, the helices were restrained in Cartesian space using a harmonic 
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potential of 10 kcal/mol, as it turned out that the helices moved too much if they were not 
restrained, causing disruption of the conserved protein core. The nonbonded cutoff radius 
was set at 12 Å. The initial temperature in the system was 0 Kelvin, and the temperature was 
increased until the reference temperature in which the system was to be kept, 300 Kelvin, 
was reached. 500,000 MD steps were run with a time step of 0.001 ps, resulting in a 500 ps 
MD simulation.  
 
3.3 Ramachandran plot 
 
The ICM program was used to generate Ramachandran plots of the structure both after the 
refinement by ICM and after the model had been refined by ICM and AMBER (500 ps MD 
simulation). The Ramachandran plots were generated in order to determine if there were 
many amino acids except glycine that had psi and phi angles outside their allowed regions. 
Many amino acid residues outside their allowed regions in a model may indicate that the 
model is not optimal. The Ramachandran plot of the 5-HT1E receptor refined by ICM is 
presented in figure 12.  
 
3.4 Construction of ligand models 
 
The xLEaP program of the AMBER molecular package was used to construct models of the 
ligands seen in figure 5 for docking. The ligands were built in xLEaP using the GAFF force 
field. After constructing the ligands, the ANTECHAMBER program of AMBER was used to 
create prep files with BCC charges for docking.  
 
The SANDER program was used to minimise the ligands. The first 500 minimisation 
cycles were performed using the steepest descent algorithm, followed by 2000 cycles of 
conjugate gradient minimisation. After minimisation, pdb files were generated from the 



























Figure 5. Two-dimensional representation of the nonprotonated forms of the ligands generated in AMBER 
























Figure 5 continued. Two-dimensional representation of the nonprotonated forms of the ligands generated in 
AMBER and docked in ICM. Isomeric forms of ligand 7, ligand 9 and ligand 10 are not shown. 
 
 33
3.5 Docking of ligands in the 5-HT1E receptor 
 
The aspartate residue in TMH3, D102, and its neighbours within 5 Å were selected as the 
main binding region for ligand interaction based on mutational studies of other receptors. As 
seen in figure 5, the ligands to be docked in this project are very similar and the batch 
docking method was therefore used. Batch docking is a docking procedure where the ligands 
are converted to mol files and contained in the same file. Instead of docking each ligand 
separately, all ligands are docked in one run and the results are displayed in the order the 
ligands are placed in the file containing all ligands. 
 
ICM performs docking of fully flexible ligands in a rigid receptor using a Monte Carlo 
minimisation procedure in internal coordinates to find the global minimum of the energy 
function. A torsional or positional conformation change, followed by local minimisation, 
is performed at each step.  
 
3.6 Calculation of binding energy  
 
The docking results were observed and ligand orientations (poses) that were outside the 
defined binding area were discarded. Ligand poses that were in the binding area but where 
the ligands terminal amine moieties were not in the proximity of the side chain oxygen atoms 
of the aspartate residue D102 were also discarded, as well as the poses that were very close to 
or colliding with receptor residues. The poses of the ligands that do not contain a terminal 
amine moiety were accepted when they were located in the putative binding area of the 
receptor. 
 
The calcBindingEnergy macro of ICM was used to calculate the energy of binding of the 
accepted ligand poses to the receptor. This macro evaluates the binding of each ligand in 
complex with the receptor by estimating the electrostatic, hydrophobic and entropic binding 





3.7 Minimisation of receptor and ligand complexes in AMBER 
 
The results from the molecular docking in ICM showed that some of the ligand poses in the 
putative binding area were very close to receptor residues and some seemed to be colliding 
with the residues, while the ligand poses for two ligands, 5-methoxytryptamine and the R-
form of tryptophanol, all had positive binding energy. In an attempt to further improve the 
results from the docking study in ICM, the SANDER program of AMBER was used to 
minimise each accepted receptor-ligand complex. 
 
The Gaussian 03 program was used to assign the ligands RESP charges for energy 
minimisation in AMBER, as RESP charges are the charges suggested for AMBER 
calculations. After the energy minimisation of the receptor-ligand complexes, the SANDER 
program of AMBER was used to convert the restart coordinate files from the energy 
minimisation to pdb files that were loaded in ICM. The new binding energies of the 





















4.1 Homology modeling 
 
4.1.1 Hydropathy plot of the 5-HT1E receptor sequence 
 
Figure 4 shows a hydropathy plot of the 5-HT1E receptor sequence using a window size 
of 9. 
 
Figure 6 Kyte-Doolittle Hydropathy plot of the 5HT1E receptor sequence. The window size is 9 was used to 
generate the hydropathy scores. Peaks that have scores greater than 1.8 (indicated by red line) show 




4.1.2 Alignment of the 5-HT1E receptor and rhodopsin amino acid sequences 
 
Figure 7 shows the alignment of the 5-HT1E receptor sequence and the rhodopsin B chain 




Figure 7. Alignment of the 5-HT1E receptor sequence and the rhodopsin B chain sequence (1u19_b) by 




4.1.3 5-HT1E receptor structure  
The 5-HT1E receptor model that had only been refined in ICM was used to interpret the 
results in this thesis. Figure 6 shows the model of the 5-HT1E receptor constructed in ICM 
with the putative binding area displayed. The binding area is located toward the extracellular 
side, beneath the beta strand motif of the second extracellular loop. Figure 8 shows that the 
putative binding area of the 5-HT1E receptor is buried between the helices toward the 
extracellular side of the membrane beneath two beta strands of the second extracellular 
loop. The figure shows, in addition to the seven transmembrane helices, the presence of 
two α helices in the longer third intracellular loop and one α helix located precisely after 
the end of transmembrane helix 7 in the C-terminal end of the receptor that runs along the 
membrane. 
                                I                                                                                                II 
 













Figure 8. 5-HT ligand pose A, tryptamine poses B and D, and S-5-hydroxy-tryptophane ethylester ligand 
pose A displayed using skin representation. The receptor viewed in the membrane plane (I) and from the 
cytoplasmic side (II). The residues that are displayed are the same as those displayed in the other figures.  









Figure 9. The 5-HT1E receptor. (I) The parts of the transmembrane helices of the 5-HT1E receptor toward 
the extracellular side shown in membrane plane and localisation of the D102 in transmembrane helix 3 
relative to the second extracellular loop containing two β strands (represented by green arrows). The 
disulfide bridge between C95 and C173 is also shown. The transmembrane regular α helices are coloured in 
red and pi and 310 helices in blue and purple, respectively. (II) Localisation of residues R120 (R3.50) and 
E286 (E6.30) at the intracellular part of the 5-HT1E receptor. 
 
Figure 9 shows the localisation of the aspartate of transmembrane helix 3 relative to the 
second extracellular loop and the localisation of the two residues R120 and E286 
suggested to be important in receptor activation. The major difference seen when 
comparing the model of the 5-HT1E receptor refined in ICM with that refined in both 
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ICM and AMBER, are in the loop areas. Representations of the electrostatic potential of 


















Figure 10. 5-HT1E receptor model viewed in the membrane plane (I) and from the extracellular side (II). 
Clipping plane has been used to expose the ligand binding area of the receptor. Red colour indicates 
negatively charged areas, blue colour indicates positively charged areas, white colour indicates neutral 























Figure 11. The 5-HT1E receptor model coloured by EPS viewed in the membrane plane. Red colour 
indicates negatively charged areas, whereas blue colour indicates positively charged areas. 
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4.1.4 Ramachandran plot  
Figure 9 shows the Ramachandran plot of the 5-HT1E receptor refined in ICM. The 
Ramachandran plot of the receptor after refinement in both ICM and AMBER showed 
that the exact same amino acid residues had psi and phi angles outside the allowed areas 
and is not shown. 
 
Figure 12. Ramachandran plot of the 5-HT1E receptor model refined in ICM showing allowed combinations 
of the conformational angles phi and psi in blue areas. Each point in the plot represents psi and phi values 
for an amino acid residue.  
 
There are 21 non-glycine amino acid residues that are outside their allowed regions in the 
Ramachandran plot. Five are located in the N-terminal part of the structure (M1, T7, 
M12, A13, R15), one in the first intracellular loop close to transmembrane helix 2 (H54), 
one is located at the boundary of transmembrane helix 2 and the first extracellular loop 
(T125) and one is located at the boundary of transmembrane helix 4 and the second 
extracellular loop (P156). There are three amino acid residues that are outside their 
allowed regions in the second extracellular loop: L166, which is located in the first β 
 42
strand of this loop, and two consecutive proline residues (P168 and P169), which form a 
motif known to end secondary structure elements, which are located at the end of the first 
β strand and causes a kink in the structure of the loop at this location. Another residue 
outside the allowed region is found at the boundary of the second extracellular loop and 
the fifth transmembrane helix (D178), while one residue is located in the middle of 
transmembrane helix 5, amino acid residue F191. This residue is found in the pi-helix of 
this transmembrane helix. Four other residues outside their allowed regions are located in 
the third intracellular loop, namely S232, F233, S235 and C236. The last non-glycine 
residues outside the allowed regions of the Ramachandran plot are found at the boundary 
of transmembrane helix 6 and the third extracellular loop (S317), and precisely after the 
helix that runs along with the plasma membrane in the cytoplasm (helix 8), the residues 
C361, R362, and E363.  
 
The Ramachandran plot shows that most of the residues are located in right-handed α 
helices but it also shows the presence of a short left-handed α helix. The plot further 
shows the presence of β strands. 
 
4.2 Docking results 
 
As the results after docking of the ligands in the 5-HT1E receptor model refined in both 
ICM and AMBER were disappointing (see calculated binding energies in table 4), the 
results generated by docking in the 5-HT1E receptor model refined in ICM were chosen to 
be interpreted here. The docking results from the docking in the ICM refined 5-HT1E 
receptor model are presented in figure 13 and in appendix 2.  
 
4.2.1 Docking results, 5-HT 
 
The results from docking of 5-HT in the 5-HT1E receptor are presented in figure 10. 
Figure 5 shows the two-dimensional representation of the ligand docked. 
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Ligand pose A 5-HT 
Ligand pose B 
Figure 13. 5-HT in the putative binding site of the 5-HT1E receptor model. Alpha helices are displayed in 
red, 310/phi in blue/purple and the receptor amino acid side chains and the ligand are displayed by atom 




Ligand pose A (∆G: -0.94 kcal/mol) forms five hydrogen bonds to receptor residues. 
Four of the hydrogen bonds are between the ligand protonated amine terminal and the 
carboxyl side chain group of D102 and one between the ligand 5-hydroxyl group to the 
receptor residue Y334 main chain oxygen atom. 
 
Ligand pose B (∆G: -0.38 kcal/mol) forms four hydrogen bonds with the receptor 
residues. One hydrogen bond is formed between the ligand indole amine group and the 
backbone oxygen atom of receptor residue T330 and three hydrogen bonds are formed 
between the ligand protonated amine terminal and the side chain carboxyl group of 
residue D102.  
 
4.2.2 Docking results, Tryptamine 
 
The results from docking tryptamine in the 5-HT1E receptor are presented in appendix 
A2.1. Figure 5 shows the two-dimensional representation of the ligand docked. 
 
Ligand pose A  (∆G: -3.90 kcal/mol) forms three hydrogen bonds with the receptor. Two 
hydrogen bonds are formed between the ligand amine terminal moiety and the side chain 
carboxyl group of residue D102, and one hydrogen bond is formed between the ligand 
indole amine group and the main chain oxygen atom of D102.  
 
Ligand pose B (∆G: -1.97 kcal/mol) forms five hydrogen bonds with receptor residues. 
Two hydrogen bonds are formed between the ligand terminal amine moiety and the D102 
side chain carboxyl group and three hydrogen bonds are formed to the D102 side chain 
oxygen atom.  
 
Ligand pose C (∆G: -1.94 kcal/mol) is positioned in almost exactly in the same position 
as ligand pose B and forms similar hydrogen bonds.  
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Ligand pose D (∆G: -0.44 kcal/mol) forms two hydrogen bonds with receptor residues. 
One hydrogen bond is formed between the ligand terminal amine moiety and the D102 
side chain carboxyl group and one is formed to the Y334 side chain hydroxyl group.  
 
4.2.3 Docking results, α-Methylserotonin, R-form 
 
The result of docking of R-form of α-Methylserotonin in the 5-HT1E receptor model is 
shown in appendix A2.2a. Figure 5 shows the two-dimensional representation of the 
ligand docked. 
 
Ligand pose A (∆G: -1.05 kcal/mol) forms three hydrogen bonds to the receptor: two 
hydrogen bonds are formed from the ligand terminal amine moiety to the receptor residue 
D102 side chain carboxyl oxygen atoms, and one hydrogen bond from its indole amine 
group to the backbone oxygen atom of residue T330. Figure 5 shows the two-dimensional 
representation of the ligand docked. 
 
4.2.4 Docking results, α-Methylserotonin, S-form 
 
The results from docking of the S-form of α-Methylserotonin in the 5-HT1E receptor 
model are presented in appendix A2.2b. Figure 5 shows the two-dimensional 
representation of the ligand docked. 
 
Ligand pose A (∆G: -4.07 kcal/mol) forms seven hydrogen bonds to the receptor 
residues. Four hydrogen bonds are formed between the ligand protonated amine terminal 
and the D102 side chain carboxyl group, and one hydrogen bond from the ligand 5-
hydroxyl group to the C106 backbone nitrogen atom and to the D102 backbone oxygen 
atom. There is also one hydrogen bond between the ligand indole amine group and the 
side chain hydroxyl group of residue S337.  
 
Ligand pose B (∆G: -3.89 kcal/mol) forms one hydrogen bond from the terminal amine 
moiety and the D102 side chain oxygen atom od2, and three hydrogen bonds are formed 
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between the amine moiety and the main chain D102 oxygen atom. In addition, one 
hydrogen bond is formed between the ligand 5-hydroxyl group and the D102 hydroxyl 
group and two hydrogen bonds to the Y334 hydroxyl group.  
 
Ligand pose C (∆G: -1.73 kcal/mol) forms two hydrogen bonds to the receptor residue 
D102 side chain carboxyl oxygen atoms from the ligand amine terminal moiety and one 
hydrogen bond to the Y334 hydroxyl group. In addition there are hydrogen bonds 
between the ligand indole amine group and the backbone oxygen atom of residue T330, 
and between the ligand 5-hydroxyl group and the D102 backbone oxygen atom.  
 
4.2.5 Docking results, 5-Methoxytryptamine 
 
The result from docking of 5-Methoxytryptamine in the 5-HT1E receptor is presented in 
appendix A2.3. Figure 5 shows the two-dimensional representation of the ligand docked. 
 
The two poses of this ligand that were located in the putative binding area of the 5-HT1E 
receptor had positive binding energy. The ligand pose with the best binding energy (∆G 
4.44 kcal/mol) is presented here. This ligand pose formed one hydrogen bond from its 
terminal amine to the side chain oxygen atom of residue D102. The receptor-ligand 
complex was energy minimised using the SANDER program of AMBER, which resulted 
in negative binding energy for the complex (∆G = -5.53 kcal/mol). 
 
4.2.6 Docking results, 3-(2-Bromoethyl)-indole 
 
The results from docking of 3-(2-Bromoethyl)-indole in the 5-HT1E receptor are shown in 
appendix A2.4. This ligand does not contain a terminal amine moiety and ligand poses 
were accepted when they were positioned in the putative binding area of the receptor. 
Figure 5 shows the two-dimensional representation of the ligand docked. 
 
Ligand pose A (∆G: -2.36 kcal/mol) forms one hydrogen bond to the receptor, namely 
between the ligand 5-hydroxyl group and the carboxyl side chain group of residue D102.  
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Ligand pose B (∆G: -2.00 kcal/mol) forms one hydrogen bond to the carboxyl group of 
residue D102 from the ligand 5-hydroxyl group. 
 
Ligand pose C (∆G: -1.68 kcal/mol) forms one hydrogen bond to the carboxyl group of 
residue D102 from the ligand 5-hydroxyl group.  
 
4.2.7 Docking results, 3-(2-Hydroxyethyl)-indole 
 
The results from docking of 3-(2-Hydroxyethyl)-indole in the 5-HT1E receptor are 
presented in appendix A.2.5. This ligand does not contain a terminal amine moiety and 
the ligand poses accepted were positioned in the putative binding area of the receptor. 
Figure 5 shows the two-dimensional representation of the ligand docked. 
 
Ligand pose A (∆G: -3.24 kcal/mol) forms one hydrogen bond between the ligand side 
chain hydroxyl group and the side chain amine group of residue N336.   
 
Ligand pose B (∆G: -2.31 kcal/mol) forms three hydrogen bonds to receptor residues. 
Two hydrogen bonds are formed between the ligand side hydroxyl group and the 
backbone nitrogen atoms of N336 and S337, and one hydrogen bond between the ligand 
indole ring amine group and the main chain oxygen of residue D102.  
 
Ligand pose C (∆G: -1.98 kcal/mol) forms four hydrogen bonds. One hydrogen bond is 
formed between the ligand side chain hydroxyl group and the backbone oxygen atom of 
residue D102 and the C106 side chain, one between the ligand indole amine group and 
the main chain oxygen atom of residue C173 and one to the side chain oxygen of T174.   
 
Ligand pose D (∆G: -0.21 kcal/mol) forms hydrogen bonds to the carboxyl group of the 
D102 side chain from the indole amine group, as well as from the ligand hydroxyl group 




4.2.8 Docking results, 2-Methyl-5-hydroxytryptamine 
 
The result from docking 2-Methyl-5-hydroxytryptamine in the 5-HT1E receptor is shown 
in appendix A2.6. Figure 5 shows the two-dimensional representation of the ligand 
docked. 
 
Ligand pose A (∆G: -2.99 kcal/mol) is the only ligand pose of this ligand in the putative 
binding area of the 5-HT1E receptor. The ligand forms seven hydrogen bonds to residue 
D102 and one hydrogen bond to residue Y334: There are three hydrogen bonds from the 
ligand terminal amine to the main chain oxygen atom of D102, two bonds from the 
terminal amine to the carboxyl group of the D102 side chain, two hydrogen bonds 
between the D102 carboxyl side chain group and the ligand 5-hydroxyl group, and one 
hydrogen bond between the ligand 5-hydroxyl group and the side chain hydroxyl group 
of residue Y334.  
 
4.2.9 Docking results, Tryptophanol, R-form 
 
The results from docking of the tryptophanol R-form in the 5-HT1E receptor is shown in 
appendix A2.7a. Figure 5 shows the two-dimensional representation of the ligand docked. 
 
All five ligand poses of this ligand that were located in the putative binding area of the 5-
HT1E receptor had positive binding energy. The ligand pose with the best binding energy 
(∆G 4.80 kcal/mol) is presented here. This ligand forms five hydrogen bonds to residue 
D102; two from the ligand terminal amine to the carboxyl group of residue D102 and two 
hydrogen bonds to the backbone oxygen atom of the residue. There is also a hydrogen 
bond between the ligand indole amine group and the side chain hydroxyl group of residue 
S337. The receptor-ligand complex was energy minimised using the SANDER program 




4.2.10 Docking results, Tryptophanol, S-form 
 
The results from docking of the tryptophanol S-form in the 5-HT1E receptor is shown in 
appendix A2.7b. Figure 5 shows the two-dimensional representation of the ligand 
docked. 
 
Ligand pose A (∆G: -4.16 kcal/mol) is the only conformation of the S-form of 
tryptophanol. Six hydrogen bonds are formed between the ligand and residue D102: five 
from the ligand terminal amine to the side chain carboxyl group of residue D102 and one 
between the ligand side hydroxyl group and the main chain oxygen atom of residue 
D102. From the ligand hydroxyl group there is also one hydrogen bond to the backbone 
nitrogen atom of residue C106 and one to the backbone oxygen atom of residue V101.  
 
4.2.11 Docking results, Methyl-3-indoylacetate 
 
The results from docking of methyl-3-indoylacetate in the 5-HT1E receptor are presented 
in appendix A2.8. This ligand does not contain any terminal amine moiety and the ligand 
poses accepted were positioned in the putative binding site of the 5-HT1E receptor. Figure 
5 shows the two-dimensional representation of the ligand docked. 
 
Ligand pose A (∆G: -2.22 kcal/mol) forms nine hydrogen bonds with the receptor. There 
are two hydrogen bonds between the ligand side chain methylacetate oxygen atoms and 
residue T174 side chain oxygen and one hydrogen bond to the Q172 side chain amine 
group. There are also three hydrogen bonds between the ligand methylacetate oxygen 
atoms and the side chain amine of residue K310, and one hydrogen bond to the side chain 
carboxyl group of D102 and one to the hydroxyl group of Y334.  
 
Ligand pose B (∆G: -0.77 kcal/mol) forms eight hydrogen bonds with the receptor. There 
is one bond between the ligand indole amine group and the carboxyl group of residue 
D102, one hydrogen bond between the ligand side chain carboxyl group and the side 
chain amine group of residue Q172, two hydrogen bonds from the ligand methylacetate 
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oxygen atoms to T174 side chain hydroxyl group, and four hydrogen bonds between the 
ligand side chain methylacetate oxygen atoms and the terminal amine group of residue 
K310. 
 
4.2.12 Docking results, Tryptophane ethylester , R-form 
 
The results from docking of the R-form of tryptophane ethylester in the 5-HT1E receptor 
are shown in appendix A2.9a. Figure 5 shows the two-dimensional representation of the 
ligand docked. 
 
Ligand pose A (∆G: -6.91 kcal/mol) forms three hydrogen bonds with the 5HT1E 
receptor. One hydrogen bond is formed between the ligand terminal amine moiety and 
the carboxyl group of residue D102. In addition, the ligand side chain oxygen atoms form 
one hydrogen bond to the S337 backbone nitrogen atom, and one hydrogen bond to the 
side chain amine group of residue N336.  
 
Ligand pose B (∆G: -1.76 kcal/mol) forms six hydrogen bonds with the 5HT1E receptor. 
There are three hydrogen bonds between the ligand amine terminal and the backbone 
oxygen atom of residue D102 and one hydrogen bond to the carboxyl group of residue 
D102. Further, two hydrogen bonds from the ligand side chain oxygen group (o1) to the 
backbone nitrogen atom of residue S337 and the side chain amine group of residue N336, 
respectively, are formed. 
 
4.2.13 Docking results, Tryptophane ethylester, S-form 
 
The results of docking of the S-form of tryptophane ethylester in the 5-HT1E receptor are 
shown in appendix A2.9b. Figure 5 shows the two-dimensional representation of the 
ligand docked. 
 
Ligand pose A (∆G: -35.88 kcal/mol) forms four hydrogen bonds to the 5HT1E receptor. 
There are three bonds between the ligand terminal amine moiety and residue D102 side 
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chain carboxyl group. In addition, there is one hydrogen bond between the terminal 
amine moiety and the hydroxyl group of the Y334 side chain. 
 
Ligand pose B (∆G: -11.21 kcal/mol) forms seven hydrogen bonds with the receptor. 
Four hydrogen bonds are formed between the amine terminal and the side chain carboxyl 
group of residue D102. In addition, there are two hydrogen bonds between the ligand side 
chain oxygen atoms and the Y334 side chain hydroxyl group and one hydrogen bond to 
the side chain amine group of residue Q172.  
 
Ligand pose C (∆G: -10.83 kcal/mol) forms six hydrogen bonds with the receptor. There 
are two hydrogen bonds between the ligand terminal amine moiety and the carboxyl 
group and one to the backbone oxygen of residue D102, one hydrogen bond between the 
ligand indole amine group and the Y334 backbone oxygen atom, as well as two hydrogen 
bonds from the ligand side chain oxygen atoms to the N336 amine side chain group.  
 
Ligand pose D (∆G: -9.30 kcal/mol) forms seven hydrogen bonds with the 5HT1E 
receptor. There are two hydrogen bonds between the ligand terminal amine moiety and 
the carboxyl group of D102, as well as three hydrogen bonds from the amine terminal to 
the backbone oxygen atom of D102. There are also two hydrogen bonds from the ligand 
side chain oxygen groups to the side chain nitrogen atom of residue N336.  
 
Ligand pose E (∆G: -7.03 kcal/mol) forms five hydrogen bonds with the 5HT1E receptor. 
One hydrogen bond is formed between the ligand terminal amine moiety and the 
carboxyl side chain group of residue D102, whereas two hydrogen bonds are formed 
between the ligand amine terminal and the backbone oxygen group of residue D102. A 
hydrogen bond is also formed between the ligand indole amine group and the Y334 main 
chain oxygen atom and between the ligand side chain double bonded oxygen atom and 
the side chain amine group of residue N336.  
 
Ligand pose F (∆G: -6.80 kcal/mol) forms four hydrogen bonds with the receptor; three 
of the hydrogen bonds are between the ligand terminal amine moiety and the side chain 
 52
carboxyl group of residue D102. The last hydrogen bond is formed between the ligand 
indole amine group and the side chain hydroxyl group of residue S337.  
 
Ligand pose G (∆G: -4.85 kcal/mol) forms seven hydrogen bonds with the 5HT1E 
receptor. Three hydrogen bonds are formed between the ligand terminal amine and the 
D102 backbone oxygen atom, whereas one hydrogen bond is formed to the carboxyl side 
chain group of residue D102. There are two hydrogen bonds between the o1 side chain 
oxygen of the ligand and the side chain amine group of the N336. In addition, one 
hydrogen bond between the ligand indole amine group and the backbone oxygen atom of 
residue V71 is formed.  
 
Ligand pose H (∆G: -3.18 kcal/mol) forms two hydrogen bonds with the receptor. Both 
bonds are between the ligand terminal amine moiety and the side chain carboxyl group of 
residue D102. 
 
Ligand pose I (∆G: -0.10 kcal/mol) forms six hydrogen bonds with the receptor. Three 
hydrogen bonds are formed between the ligand terminal amine and the side chain 
carboxyl group of residue D102 and two hydrogen bonds are formed to the backbone 
D102 oxygen atom. There is also one hydrogen bond between the o2 side chain oxygen 
atom of the ligand and the C106 side chain sulphur group.  
 
4.2.14 Docking results, 5-Hydroxy-tryptophane ethylester, R-form 
 
The results from docking of the R-form of 5-hydroxy-tryptophane ethylester in the 5-
HT1E receptor are presented in appendix A2.10a. 
 
Ligand pose A (∆G: -3.96 kcal/mol) forms eight hydrogen bonds with the receptor. One 
hydrogen bond is formed between the D102 side chain carboxyl group and three 
hydrogen bonds between the D102 backbone oxygen atom and the ligand amine terminal, 
three hydrogen bonds between the ligand side chain oxygen groups and the side chain 
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nitrogen group N336, and one hydrogen bond between the side chain hydroxyl group of 
residue S337 and the indole amine group of the ligand.  
 
Ligand pose B (∆G: -1.37 kcal/mol) forms six hydrogen bonds with the receptor. There 
are formed two hydrogen bonds between the ligand amine terminal and the D102 side 
chain carboxyl group and one hydrogen bond to the D102 main chain oxygen atom, as 
well as one hydrogen bond from the ligand side chain double bonded oxygen atom to the 
C106 side chain sulphur group, one hydrogen bond to the main chain oxygen atom of 
M103 from the ligand indole amine group, and one hydrogen bond between the ligand 
amine terminal and the hydroxyl group of residue Y334. 
 
4.2.15 Docking results, 5-Hydroxy-tryptophane ethylester, S-form 
 
The results from docking of the S-form of 5-hydroxy-tryptophane ethylester in the 5-
HT1E receptor are presented in appendix A2.10b. 
 
Ligand pose A (∆G: -5.65 kcal/mol) forms ten hydrogen bonds with the receptor. There 
are four bonds between the ligand and residue D102; two are between the ligand terminal 
amine and the side chain carboxyl group and two are between the ligand terminal amine 
and the backbone oxygen atom. There is one hydrogen bond between the indole amine 
group of the ligand and the main chain oxygen group of residue G333, one hydrogen 
bond between the ligand 5-hydroxyl group and side chain oxygen atom of residue N340, 
one hydrogen bond between the ligand 5-hydroxyl group and the side chain amine group 
of residue N336 and one between the ligand side chain oxygen groups and the side chain 
amine group of residue N336, the main chain nitrogen of residue S337, as well as one to 
the S109 side chain hydroxyl group. 
 
Ligand pose B (∆G: -2.76 kcal/mol) forms nine hydrogen bonds with the 5HT1E receptor. 
There are five hydrogen bonds between the ligand amine terminal and the carboxyl group 
of residue D102, two hydrogen bonds between the ligand 5-hydroxyl group and S109 
hydroxyl side chain group and one hydrogen bond to the C105 backbone oxygen group. 
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Finally, there is one hydrogen bond between the ligand double bonded oxygen side chain 
atom and the side chain sulphur group of residue C106. 
 
4.2.16 Calculation of binding energy  
 
Tables 3 and 4 show the binding energies that were calculated using the 
calcBindingEnergy macro in ICM after docking of the ligands in the model of 5-HT1E 
receptor refined by ICM and in the model of the 5-HT1E receptor refined by both ICM 
and AMBER. The results show that more ligands are positioned in the putative binding 
site of the ICM refined 5-HT1E receptor model than in the ICM and AMBER refined 
model of the 5-HT1E receptor. The accepted ligand pose of each ligand with the best 
binding energy is named ligand pose A, the second best ligand pose B and so forth. 
 
4.2.17 Minimisation of receptor-ligand complexes  
 
The results from the minimisation of the receptor-ligand complexes in AMBER are not 
shown, except for the results of the minimisation of the ligand poses with best binding 
energy of the two ligands where all ligand poses had positive binding energy after 
docking in ICM. These results are presented in appendix A2.3 and A2.7b. The reason for 
not showing all results is that problems were encountered during the minimisations in 
AMBER. For many of the receptor-ligand complexes the minimisation stopped early 
because of reported problems in the receptor structure far from the putative binding site 












Table 3. Binding energy, ICM model, ∆G (kcal/mol). A-K denote different ligand poses of each ligand. 
 
 5-HT Tryptamine α-Methylserotonin, R α-Methylserotonin, S 
A -0.94 -3.9 -1.05 -4.07 
B -0.38 -1.97  -3.89 
C  -1.94  -1.73 








A 4.44 -2.36 -3.24 -2.99 
B  -2 -2.31  
C  -1.68 -1.98   
D   -0.21   
 Tryptophanol, R Tryptophanol, S Methyl-3-indoylacetate 
Tryptophane   
ethylester, R 
A 4.8 -4.16 -2.22 -6.91 










A -35.88 -3.96 -5.65  
B -11.21 -1.37 -2.76  
C -10.83    
D -9.3    
E -7.03    
F -6.8     
G -4.85     
H -3.18      
I -0.1     
 
Table 4. Binding energy, ICM and AMBER refined model, ∆G (kcal/mol). A-E denote different ligand 
poses of each ligand. 
 
 5-HT Tryptamine α-Methylserotonin, R α-Methylserotonin, S 
A -0.49 -0.56 -1.69 -9.95 








A -8.14 None -0.99 -4.64 
B -2.87    
 Tryptophanol, R Tryptophanol, S Methyl-3-indoylacetate 
Tryptophane   
ethylester, R 
 None None None None 
 








A -21.49 -4.54 -7.31  
B -8.33  -6.32  
C -7.33  -4.43  
D -1.99  -2.38  




5.1 Sequence analysis and receptor structure 
 
The hydropathy plot of the 5-HT1E receptor sequence in figure 6 predicts that there may 
be at least six hydrophobic stretches corresponding to transmembrane helices in the 5-
HT1E receptor protein, as six peaks in the plot have hydropathy scores over 1.8. The plot 
also indicates two less hydrophobic regions (hydropathy scores of approximately 1) 
following the sixth peak. These peaks correspond to the seventh transmembrane helix and 
the intracellular C-terminal helix seen in the structure of the model generated by ICM. 
The hydropathy plot also predicts that there are two additional hydrophobic stretches in 
the region between peak 5 and 6, that corresponding to the third, longer intracellular loop. 
Comparison of the hydropathy plot and the model of the 5-HT1E receptor generated by 
homology modeling using bovine rhodopsin as a template, shows that ICM predicts two 
α helices in the third intracellular loop of the 5-HT1E receptor – one ICL3 α helix toward 
the N-terminal part of the loop consisting of amino acid residues 206-224 and one ICL3 α 
helix toward the C-terminal end of the loop consisting of amino acid residues 235-245. In 
figures 10 and 11, where the electrostatic potential of the 5-HT1E receptor model is 
shown, these two helices may at least account for some of the electronegatively charged 
areas seen in this otherwise electropositive area.  
 
The results of the hydropathy plot are in accordance with the results obtained from the 
alignment of the 5-HT1E receptor sequence with that of bovine rhodopsin, shown in 
figure 7, and the model built based on this alignment, shown in figures 9-11. The 
alignment of rhodopsin and the 5-HT1E receptor in ICM predicts that helix 1 is comprised 
of residues 19-49, helix 2 of residues 56-85, helix 3 of residues 91-124, helix 4 of 
residues 139-157, helix 5 of residues 179-203, helix 6 of residues 281-315, and helix 7 of 
residues 323-346, followed by a helix consisting of amino acid residues 348-359. In this 
last helix, residue F350, which corresponds to residue F313 in rhodopsin, is highly 
conserved within family A of GPCRs. 
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The alignment of the 5-HT1E receptor and the sequence of bovine rhodopsin in ICM 
reveals that the two proteins share 14 percent sequence homology. Normally, such low 
sequence homology between the template and target structure would be detrimental for 
the prediction of the target structure by homology modeling, as it is believed that the 
template and target sequences should have at least 50 percent of their residues in common 
in order to obtain accurate models. Membrane proteins, however, despite low sequence 
homology, fold into similar three-dimensional structures. Functional important residues, 
which are important for proper folding of the structure or involved in the signalling 
mechanisms of the receptor, are highly conserved among such membrane proteins and 
may be used to classify the different proteins. The highly conserved residues among 
family A GPCRs that place the 5-HT1E receptor in this family are residues N40 in TMH1, 
D68 in TMH2, R120 in TMH3, W147 in TMH4 and residues P194, P306, and P341 of 
TMH5-7, respectively. Further, the presence of the biogenic receptor fingerprint residues 
D3.32 (D102), W7.40 (W331) and Y7.43 (Y334) in the sequence shows that this 
sequence indeed encodes a biogenic amine receptor, as no other family A GPCR contains 
these three residues. In addition, residues F6.51 (F307) and F6.52 (F308) are only found 
in mammalian 5-HT receptors and show that the sequence encodes a G-protein coupled 
5-HT receptor. 
 
As the alignment of the 5-HT1E receptor and rhodopsin amino acid sequences in figure 7 
shows, there is no sequence homology between the two sequences in the N-terminal, 
extracellular parts of the proteins. The 5-HT1E receptor and bovine rhodopsin also share 
low sequence homology in the first transmembrane helix, though many residues are 
similar in that they are hydrophobic. Transmembrane helix 2 shows a somewhat more 
sequence homology between the sequences than the first transmembrane helix; however, 
rhodopsin is not a biogenic amine receptor and does not have an aspartate residue in 
position 3.32 but an alanine residue. As the negatively charged side chain carboxyl group 
of the D3.32 residue is thought to form an ionic interaction with the positively charged 
biogenic amine ligands, it is not optimal that these residues differ in the 5-HT receptors 
and rhodopsin.  
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The 5-HT1E receptor forms a disulfide bond between cysteine residue 95, which is 
located close to the extracellular side in transmembrane helix 3, and cysteine residue 173, 
found in the β strand that is located toward the C-terminal end of the second extracellular 
loop. This disulfide bridge is highly conserved and occurs in rhodopsin as well as in all 
the 5-HT receptors. Disulfide bonds in general are though to stabilise protein three-
dimensional structures and in family A GPCRs, this disulfide bridge covalently attaches 
the second extracellular loop in the physical proximity of the binding site. Figure 9 shows 
the location of this loop relative to D102 (D3.32) in the 5-HT1E receptor. The 5-HT1E 
receptor has three consecutive proline residues (P168, P169, and P170) in the loop 
between the β strands, which none of the other 5-HT receptors nor rhodopsin have. 
Rhodopsin and the 5-HT2B receptor have a proline residue at the first position (residue 
P180 in the rhodopsin structure and P202 in the 5-HT2B receptor). Two consecutive 
proline residues is known to disrupt secondary structure elements. 
 
Residues D119, R120, and Y121 of the 5-HT1E receptor constitute the conserved DRY 
motif which is located toward the intracellular end of the third transmembrane helix. 
R120 is the reference residue of transmembrane helix 3. This motif is highly conserved 
among family A members (Kroeze et al. 2002) and is found in all 5-HT receptors. In 
rhodopsin, the aspartate residue is a glutamic acid. Studies on rat 5-HT2A receptors 
suggest that residue R3.50 may be involved in a strong ionic interaction with residue 
E6.30, which is residue E286 in the 5-HT1E receptor structure, when the receptor is in its 
inactive state and that disturbance of this interaction may cause transmembrane helices 3 
and 6 to move apart, thereby activating the receptor. In the 5-HT1E receptor structure, the 
side chains of residues R120 and E286 are pointing toward each other, suggesting that 
this receptor activation theory may apply for the 5-HT1E receptor as well. Figure 9 shows 
the location of R120 and E286 in the 5-HT1E receptor. 
 
Transmembrane helix 6 contains a highly conserved region of amino acids FXXXW, 
where residues X vary among the receptors. In the 5-HT1E receptor sequence, this region 
corresponds to residues F300 (6.44), I301 (6.45), L302 (6.46), S303 (6.47), and W304 
(6.48); the 5-HT1E receptor is the only 5-HT receptor that has a serine residue in position 
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6.47. Rhodopsin has residues L, I, and C in position 6.45-6.47. The x-ray structure of 
rhodopsin reveals that W6.48 (which is residue 265 in rhodopsin sequence) is in close 
proximity of the retinal chromophore and is involved in the activation and release of the 
chromophore (Okada et al. 2004). In the modelled structure of the 5-HT1E receptor 
generated in this project, the tryptophan in this position is in close proximity of the 
suggested ligand binding site and may contribute to stacking of the ligands in the binding 
site  
 
Transmembrane helix 7 contains a conserved NPXXY region. In the 5-HT1E receptor this 
region corresponds to residues N340 (7.49), P341 (7.50), L 342 (7.51), L343 (7.52), and 
Y344 (7.53). Residues X vary between being leucine, isoleucine, and phenylalanine in 
the 5-HT and rhodopsin receptor sequences. It has been suggested that the aspargine in 
this motif forms hydrogen bonds with the reference residue of transmembrane helix two, 
D68, and that the residues may be important for receptor activation. The two residues are 
located close to each other in the structure of the 5-HT1E receptor (not shown).  
 
The extracellular and intracellular loops of the 5-HT receptors are the least conserved 
parts of the receptor. It has been hypothesised that the ligands must pass through a 
channel made up of residues in the first and third extracellular loops and the extracellular 
parts of the transmembrane helices in order to reach their binding site buried between the 
helices (Kristiansen 2004). The residue corresponding to W88 in the 5-HT1E receptor 
sequence in the first extracellular loop is conserved among all the 5-HT receptors. The 
residue in this position in rhodopsin is another aromatic residue, namely phenylalanine. 
Except for this conserved residue, the sequence homology in the first extracellular loop is 
low. The second extracellular loop contains the conserved disulfide bridge that 
contributes in placing the second extracellular loop in the proximity of the receptor ligand 
binding site and makes it possible for loop residues to contact the ligands. The 5-HT1E 
receptor contains a stretch of residues in this loop that is not found in any of the other 5-
HT receptor sequences, namely residues S162, H163, R164, R165, L166 and S167. 
Residues R164-S167 constitute the N-terminal β strand of this loop.  
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Of the intracellular loops, the third intracellular loop is the longest. In the 5-HT1E 
receptor structure this loop consists of residues 204-280. This loops most likely is the site 
of G-protein coupling. 
 
The crystal structure of rhodopsin shows that rhodopsin has a helix 8 in the C-terminal 
intracellular part of the sequence (Okada et al. 2004). This helix corresponds to residues 
348-361 in the 5-HT1E receptor. 
 
Figure 12 shows the Ramachandran plot of the 5-HT1E receptor refined by ICM. The 
Ramachandran plot of the both 5-HT1E receptor models showed that the same residues 
were outside their allowed regions in both plots, showing that the molecular dynamics 
simulation did not introduce additional unfortunate angles in the structure. The 
Ramachandran plot shows that there are few residue that have psi and phi angles outside 
their allowed region in the receptor, and that the residues that are have angles outside the 
allowed regions not located in the conserved heptahelical structure of the receptors, 
except for F191, which is located in the pi helix of transmembrane helix.  
 
Figures 10 and 11 shows the 5-HT1E receptor electrostatic potential. The electrostatic 
potentials of the model indicate that the receptor has a dipolar charge distribution with the 
extracellular side mainly negative and the intracellular side mainly positive. The plasma 
membrane of cells separates positive and negative charges; the extracellular side has a 
relative excess of positive charge and the intracellular side has a relative excess of 
negative charge. The charge distribution over the membrane will therefore stabilise the 
structure of the 5-HT receptor in the membrane. This finding is in accordance with the 
‘positive inside rule’ that states that all membrane proteins are positively charged toward 







5.2 Results from docking of ligands in the 5-HT1E receptor 
 
5.2.1 Docking in the 5-HT1E receptor model refined by ICM and AMBER 
 
The ligands shown in figure 5 were docked in the model of the 5-HT1E receptor that had 
been refined by both ICM and AMBER. The results from this docking are shown in table 
4 in form of binding energies, while the binding energies from docking in the 5-HT1E 
ICM refined model are shown in table 3. 
 
The results from docking in the 5-HT1E receptor model refined by ICM and AMBER 
show that fewer ligands fitted into the putative binding site of the receptor compared to in 
the 5-HT1E receptor model refined only by ICM. Comparison of the results from the two 
dockings shows that some of the binding energies for the ligands are in the same range in 
both receptor models but some differ quite much. Some ligands, for example 3-(2-
Bromoethyl)-indole and both forms of tryptophanol, show no binding in the putative 
binding area of the model refined by both ICM and AMBER, whereas they are positioned 
in the binding area of the 5-HT1E receptor model refined only by ICM. 
 
During MD simulation in AMBER the helices were restrained in Cartesian space. 
Comparison of the two models of the 5-HT1E receptor (not shown) showed that the 
helices had not moved much during the MD simulation, as expected, indicating a stable 
receptor structure. However, the loops of the model have moved relatively much and this, 
together with some minor movement of the residue side chains, may explain the poor 
docking results obtained when performing docking in the 5-HT1E receptor model refined 
by both ICM and AMBER. As discussed earlier, the extracellular loops, especially the 
second extracellular loop, are important for ligand recognition and this may therefore 
explain the poorer results from docking of the ligands in this model than in the model 
refined only by ICM. 
 
As the refineModel macro in ICM is considered to be enough refinement of a model built 
using the homology modeling approach in order to obtain good molecular docking 
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results, and the results after docking in the ICM and AMBER refined model were poorer 
than the results from docking in the ICM refined model, the 5-HT1E receptor model 
refined by ICM was chosen to be used for interpretation of the results obtained in this 
project. 
 
5.2.2 Docking in the 5-HT1E receptor model refined by ICM 
 
The results from docking of 5-HT in the putative binding site of the 5-HT1E receptor are 
shown in figure 13, while figures showing the results from docking of the other ligands 
are shown in appendix 2. The calculated binding energies from the docking are contained 
in table 3. The figures and table only show the results where the ligands were positioned 
in the putative binding area and had negative binding energy, except for two ligands, α-
methylserotonin and the R-form of tryptophanol, for which no ligand poses positioned in 
the binding area having negative binding energy were found. Instead, the ligand pose 
with best positive binding energy of each of these two ligands are presented in appendix 
2. 
 
The results show that no ligand poses were located in close proximity of residues S186, 
T187, F191 or Y192, which are suggested to be potential hydrogen bonding residues 
(S186 and T187) and part of a hydrophobic ligand binding pocket (F191 and Y192). In 
the model, T187 and Y192 are pointing away from the ligand binding pocket toward the 
membrane. It may be that F191 is pointing in the wrong direction and might actually be 
more important than shown here. The Ramachandran plot showed that this residue had 
psi and phi angles outside the allowed region so it is possible that F191 in reality is more 
involved in ligand binding than shown in this docking study. Also, residue D327, which 
is located in position 7.36, does not either seem to be directly involved in ligand binding.  
 
Figure 8 shows the putative ligand binding area of the 5-HT1E receptor created by 
displaying the molecular surfaces of four ligand poses, 5-HT pose A, tryptamine pose B 
and D, and pose A of the S-form of 5-hydroxy-tryptophane ethylester. These ligand poses 
were chosen as they represent the areas where most ligands were positioned in this study. 
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5-HT ligand pose A is positioned such that the aromatic tyrosine reside 334 side chain 
stacks against the ligand indole ring in a sandwich fashion and the ligand terminal amine 
moiety is in close proximity of the carboxyl oxygen atoms of the D102 side chain, see 
figure 13. The indole ring of the tryptamine ligand pose B is positioned such that it is 
almost perpendicular to the aromatic side chain of residue W98 and not far from Y334, 
whereas ligand pose D is positioned in a completely other orientation, wher the indole 
ring is positioned in the proximity of the aromatic side chains of residues F300, F307, 
and F308. The results show that the side chains of these aromatic residues may be 
involved in stacking of the ligands. The terminal amine moieties of both ligand poses are 
in close proximity of the carboxyl group of residue D102 and form hydrogen bonds to 
this residue. The last ligand pose representing an area where ligands can interact with the 
receptor putative binding site of the 5-HT1E receptor, is ligand pose A of the 5-hydroxyl-
tryptophane ethylester ligand. The indole ring of this ligand pose is positioned in such a 
way that the aromatic side chain of residue W304 may be involved in stacking of this 
ligand pose.   
 
Most of the ligand poses are positioned in the same area of the putative binding site as 
ligand poses A of 5-HT and ligand pose B of tryptamine. Fewer ligands poses are found 
in the area represented by ligand pose D of tryptamine and only ligand pose A of the 5-
hydroxyl-tryptophane ethylester ligand is positioned in that area. 
 
The two ligands where all ligand poses in the binding site have positive binding energy, 
5-methyltryptamine and the R-form of tryptophanol, are not located in the same area of 
the binding site. Appendix A2.3 shows that the ligand pose of 5-methyltryptamine is 
located in the same area as ligand pose B of tryptamine and that the indole rings of these 
two ligand poses are positioned approximately in the same orientation. The receptor-5-
methoxytryptamine complex was minimised using the SANDER program of AMBER 
and comparison of the receptor-ligand complex before AMBER minimisation and after 
AMBER minimisation, see appendix A2.3, shows that the major difference before and 
after the minimisation are found in the ligand structure. The receptor residues show minor 
differences in their positions before and after the energy minimisation. The second ligand 
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where all ligand poses had positive binding energy was the R-form of tryptophanol, see 
appendix A2.7a. The indole ring of this ligand is located in the approximate same 
position as tryptamine ligand pose B. Minimisation of the receptor-R-tryptophanol 
complex resulted in negative binding energy of the complex. Only one true ligand pose of 
the S-form of tryptophanol was observed. This ligand pose show relatively good binding 
energy when compared to the binding energies of the poses of the other ligands docked 
(∆G of -4.16 kcal/mol).  
 
Of the receptor residues that the ligands form hydrogen bonds to, three are located in the 
second extracellular loop, namely residues Q172, C173, and T174. Residue C173 forms 
the disulfide bridge (to residue C95) and is conserved but the other two residues are not. 
Only rhodopsin and the 5-HT1E and 5-HT6 receptors have a glutamine residue in the 
position corresponding to Q172 in the 5-HT1E receptor. The side chain of this residue is 
involved in forming hydrogen bonds to some of the ligands. The 5-HT1E and the 5-HT1A 
receptor are the only receptors in the alignment that have threonine in the position 
corresponding to T174 in the 5-HT1E receptor. The side chain of this residue is involved 
in forming hydrogen bonds to the ligands. Further, the 5-HT1E receptor is the only 
receptor in the alignment that has a methionine residue in position 103. However, only 
one ligand forms hydrogen bonds to this residue and the bond is formed to the main chain 
not the side chain of the residue suggesting that it does not play an important role in 
ligand binding. Only one ligand forms hydrogen bonds to residue K310, which has been 
suggested may account for the pharmacological differences observed between the 5-HT1E 
and 5-HT1B receptors, namely methyl-3-indoylacetate. This ligand also forms hydrogen 
bonds to Q172 and T174.  
 
Another observation is that many of the ligand poses form many hydrogen bonds to the 
receptor residues. Lipinski’s rule-of-5 states that drugs that have the possibility of 
participating in many hydrogen bonds may not be easily absorbed, distributed, 
metabolised, or excreted in the body. The results from this docking study show that many 
of the ligands tested participate in many hydrogen bonds and may for that reason not be 
suitable drug compounds.  
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The calculation of binding energy shows that 5-HT, except for the two ligands having 
positive binding energy, is the ligand that has the lowest binding energy, the best ligand 
pose of 5-HT having a binding energy of -0.94 kcal/mol. 5-HT and the R-form of α-
methylserotonin are the only ligands having binding energies higher than -2 kcal/mol. 
The best ligand poses of ligands 3-(2-bromoethyl)-indole, 3-(2-hydroxyethyl)-indole, 2-
methyl-5-hyroxytryptamine and methyl-3-indoylacetate have binding energies in the 
range of -2 to -3 kcal/mol, whereas the best poses of ligands tryptamine, the S-form of α-
methylserotonin, the S-form of tryptophanol, and the 5-hydroxy-tryptophane ethylester 
R-form all have binding affinities of approximately -3 to -4 kcal/mol. Two ligands, the S-
form of 5-hydroxy-tryptophane ethylester and the R-form of tryptophane ethylester, have 
binding energies between approximately -5 and –7 kcal/mol, whereas the best ligand pose 
of the S-form of tryptophane ethylester has a binding energy of -35.88 kcal/mol. 
However, since all other binding energies are much higher than this value, the result is 
probably not correct.  
 
5.2.3 Experimental ligand binding study 
 
Appendix 3 contains the results from a radio ligand binding study performed by Lise 
Roman Moltzau at the Department of Pharmacology at the University of Oslo. The radio 
ligand binding study performed was a competition binding assay with the ligand and 5-
HT1E receptor expressed in HEK293 cells. Using unlabeled ligands that competed with 
[3H]5-HT the affinities for the ligands were determined by displacement of  [3H]5-HT. 
The ligands were not synthesised at the University of Oslo but bought commercially. 
None of the ligands are very good – they neither have high binding affinity nor high 
specificity for the 5-HT1E receptor. 
 
The results from this radio ligand binding study do not fit the results from the docking 
study performed here. The results from the ligand binding study show that 5-HT is the 
ligand that has best affinity for the 5-HT1E receptor, whereas the results obtained here 
show that many of the ligands have better binding energy than 5-HT. It further shows that 
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four ligands, 3-(2-bromoethyl)-indole, 3-(2-hydroxyethyl)-indole, methyl-3-
indoylacetate, D,L-tryptophan ethylester hydrochloride, and L-tryptophan ethylester 
hydrochloride have negative pKi values and most likely do not bind to the 5-HT1E 
receptor, whereas the results obtained in this docking study give relatively good binding 
energies for these ligands, in fact, the two forms of tryptophan ethylester are the ligands 
that have the best binding energies in the docking study. 5-methoxytryptamine and the R-
form of tryptophanol, the ligands where no ligand poses with negative binding energies 
were found in the docking study, are shown to bind to the 5-HT1E receptor in the radio 
ligand binding study.  
 
The ligands were not synthesised in Oslo but bought commercially. None of the ligands 
are very good – they neither have high binding affinity nor high specificity for the 5-HT1E 
receptor. 
 
The model of the 5-HT1E receptor may not be optimal. The alignment of the 5-HT1E 
receptor and rhodopsin amino acid sequences may not be completely correct and as 
residues that are important for ligand binding in the 5-HT1E receptor, such as D3.32 and 
Y7.43 are not conserved in rhodopsin, the side chains of these residues may be pointing 
in the wrong direction in the modelled structure. Rhodopsin has an alanine residue in 
position 3.32 and a lysine residue in position 7.43. Another important reason may be that 
the receptor molecule is rigid during docking in ICM. The protein flexibility is 
considered to be one of the major challenges in molecular docking; ideally protein 
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Appendix A1. Alignment of the human 5-HT receptor and bovine rhodopsin amino acid 
sequences generated by ICM. 
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Appendix A1 continued. Alignment of the human 5-HT receptor and bovine rhodopsin amino 





























Ligand pose A Tryptamine 
 
Ligand pose B 




Ligand pose C 
Ligand pose D                     
Appendix A2.1 continued. Ligand poses of tryptamine in the putative binding site of the 
5-HT1E receptor.  




























Ligand pose A                     
        α-Methylserotonin, R-form 
Appendix A2.2a Ligand pose A of α-Methylserotonin, R-form, in the putative binding 






Ligand pose A  
        α-Methylserotonin, S-form 
Ligand pose B   
Appendix A2.2b Ligand poses of α-Methylserotonin, S-form, in the putative binding site 
of the 5-HT1E receptor. 
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Ligand pose C 
Appendix A2.2b continued. Ligand poses of α-Methylserotonin, S-form, in the putative 

























































Ligand pose A    
                            5-Methoxytryptamine 
II 
Ligand pose A; ICM: blue and AMBER: red 
Appendix A2.3. 5-Methoxytryptamine in the putative binding site of the 5-HT1E receptor. 
Figure I shows the ligand pose yielding positive binding energy (∆G: 4.44 kcal/mol). 
Figure II shows the superimposition of the receptor-ligand complex before (coloured 


























Ligand pose A   
        3-(2-Bromoethyl)-indole 
Ligand pose B 
Appendix A2.4. Ligand poses of 3-(2-Bromoethyl)-indole in the putative binding site of 
the 5-HT1E receptor. 
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Ligand pose C 
Appendix A2.4 continued. Ligand poses of 3-(2-Bromoethyl)-indole in the putative 











































Ligand pose A   
        3-(2-Hydroxyethyl)-indole 
 
Ligand pose B 
Appendix A2.5. Ligand poses of 3-(2-Hydroxyethyl)-indole in the putative binding site 




Ligand pose C 
Ligand pose D 
Appendix A2.5 continued. Ligand poses of 3-(2-hydroxyethyl)-indole in the putative 



























Ligand pose A                
       2-Methyl-5-hydroxytryptamine 
Appendix A2.6. Ligand pose of 2-Methyl-5-hydroxytryptamine in the putative binding 



















































Ligand pose A   
II        Tryptophanol, R-form 
Ligand pose A, ICM: blue; AMBER: red 
Appendix A2.7a. Ligand pose of tryptophanol, R-form, in the putative binding site of the 
5-HT1E receptor. Figure I shows the ligand pose yielding positive binding energy (∆G: 
4.80 kcal/mol). Figure II shows the superimposition of the receptor-ligand complex 
before (coloured blue/light blue) and after (coloured red/orange) energy minimisation of 
the complex in AMBER. 
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Ligand pose A  
         Tryptophanol, S-form 












































Ligand pose A                      
        Methyl-3-indoylacetate 
Ligand pose B 
Appendix A2.8. Ligand poses of methyl-3-indoylacetate in the putative binding site of 



























Ligand pose A        
               Tryptophane ethylester, R-form 
Appendix A2.9a. Ligand poses of tryptophane ethylester, R-form, in the putative binding 





Ligand pose A          
                             Tryptophane ethylester, S-form 
Ligand pose B 
Appendix A2.9b. Ligand poses of tryptophane ethylester in the putative binding site of 





Ligand pose C 
Ligand pose D 
Appendix A2.9b continued. Ligand poses of tryptophane ethylester in the putative 
binding site of the 5-HT1E receptor. 
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Ligand pose E 
Ligand pose F 
Appendix A2.9b continued. Ligand poses of tryptophane ethylester in the putative 
binding site of the 5-HT1E receptor. 
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Ligand pose G 
Ligand pose H   
Appendix A2.9b continued. Ligand poses of tryptophane ethylester in the putative 
binding site of the 5-HT1E receptor. 
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Ligand pose I 
Appendix A2.9b continued. Ligand poses of tryptophane ethylester in the putative 

























































Ligand pose A    
      5-hydroxy-tryptophane ethylester, R-form  
 
Ligand pose B 
Appendix A2.10a. Ligand poses of 5-hydroxy-tryptophane ethylester, R-form, in the 
putative binding site of the 5-HT1E receptor. 
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Ligand pose A  
      5-hydroxy-tryptophane ethylester, S-form 
 
Ligand pose B 
Appendix A2.10b. Ligand poses of 5-hydroxy-tryptophane ethylester, S-form, in the 









































Appendix A3. pKi-values of the different ligands tested on the human 5-HT1E receptor by 
Lise Roman Moltzau. 
 
























































L-Tryptophan ethylester hydrochloride 
 
-3.56±2.05 
 
3 
5-Hydroxy-DL-tryptophan ethylester 
 
4.28±0.03 
 
3 
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